Breaking News

ROVI Rebrands as ROIS, Acquires U.S. Injectable Manufacturing Site

Positions ROIS as a transatlantic CDMO with direct U.S. production capacity.

Author Image

By: Charlie Sternberg

Associate Editor

ROVI’s Contract Development and Manufacturing Organization (CDMO) business unit will rebrand as ROIS and acquire a sterile injectable drug product manufacturing facility in Phoenix, Arizona from Bristol Myers Squibb. The move marks a significant expansion of the company’s global footprint and manufacturing capabilities, positioning ROIS as a transatlantic CDMO with direct U.S. production capacity. The Phoenix site spans approximately 34,000 square meters on an 80,000 square meter campus and h...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters